Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsay M Avery

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
International Journal of Antimicrobial Agents|July 26, 2018
Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hopeLindsay M Avery, David P Nicolau
The Journal of Antimicrobial Chemotherapy|May 11, 2018
Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratoryLindsay M Avery, David P Nicolau
Expert Opinion on Investigational Drugs|April 4, 2018
Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteriaLindsay M Avery, David P Nicolau
International Journal of Psychiatry in Medicine|April 16, 2016
Bipolar depression: Managing patients with second generation antipsychoticsLindsay M Avery, Shannon J Drayton
Antimicrobial Agents and Chemotherapy|September 6, 2018
Assessment of the <i>In Vivo</i> Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection ModelLindsay M Avery, Kamilia Abdelraouf, David P Nicolau
Journal of Medical Microbiology|May 4, 2019
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosaLindsay M Avery, Christina A Sutherland, David P Nicolau
International Journal of Antimicrobial Agents|December 25, 2019
Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hopeLindsay M Avery, Elias M Mullane, David P Nicolau
Antimicrobial Agents and Chemotherapy|December 18, 2019
Comparative Evaluation of the <i>In Vitro</i> Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>Elias M Mullane, Lindsay M Avery, David P Nicolau
Diagnostic Microbiology and Infectious Disease|June 20, 2019
In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing EnterobacteriaceaeLindsay M Avery, Christina A Sutherland, David P Nicolau
The Journal of Antimicrobial Chemotherapy|October 22, 2022
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combinationAndrew J Fratoni, Lindsay M Avery, David P Nicolau, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Antimicrobial Agents|July 26, 2018
Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hopeLindsay M Avery, David P Nicolau
The Journal of Antimicrobial Chemotherapy|May 11, 2018
Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratoryLindsay M Avery, David P Nicolau
Expert Opinion on Investigational Drugs|April 4, 2018
Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteriaLindsay M Avery, David P Nicolau
International Journal of Psychiatry in Medicine|April 16, 2016
Bipolar depression: Managing patients with second generation antipsychoticsLindsay M Avery, Shannon J Drayton
Antimicrobial Agents and Chemotherapy|September 6, 2018
Assessment of the <i>In Vivo</i> Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection ModelLindsay M Avery, Kamilia Abdelraouf, David P Nicolau
Journal of Medical Microbiology|May 4, 2019
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosaLindsay M Avery, Christina A Sutherland, David P Nicolau
International Journal of Antimicrobial Agents|December 25, 2019
Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hopeLindsay M Avery, Elias M Mullane, David P Nicolau
Antimicrobial Agents and Chemotherapy|December 18, 2019
Comparative Evaluation of the <i>In Vitro</i> Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>Elias M Mullane, Lindsay M Avery, David P Nicolau
Diagnostic Microbiology and Infectious Disease|June 20, 2019
In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing EnterobacteriaceaeLindsay M Avery, Christina A Sutherland, David P Nicolau
The Journal of Antimicrobial Chemotherapy|October 22, 2022
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combinationAndrew J Fratoni, Lindsay M Avery, David P Nicolau, et al.
Pageof 3